

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## CLARITY MEDICAL GROUP HOLDING LIMITED

### 清晰醫療集團控股有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1406)**

#### INSIDE INFORMATION

**(1) DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS AND  
DESPATCH OF ANNUAL REPORT FOR THE YEAR  
ENDED 31 MARCH 2025;  
AND  
(2) CONTINUED SUSPENSION OF TRADING**

This announcement is made by the board of directors (the “**Board**”) of Clarity Medical Group Holding Limited and its subsidiaries (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

#### **DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS**

Reference is made to the announcement of the Company dated 30 May 2025 in relation to the resumption guidance (the “**Resumption Guidance Announcement**”). Terms used herein shall have the same meanings as defined in the Resumption Guidance Announcement unless otherwise stated.

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the preliminary announcement for the annual results of the Group for the year ended 31 March 2025 on a date no later than three months after the end of the financial year of the Company (i.e. on or before 30 June 2025).

However, the Board wishes to inform the shareholders of the Company (the “**Shareholders**”) that there will be a delay in publication of the Company’s audited annual results for the year ended 31 March 2025 (the “**2025 Annual Results**”) as the Company is still in the process of addressing the allegations and issues set out in the Resumption Guidance Announcement which are considered by the Group’s auditor (the “**Auditor**”) as relevant to the audit of the 2025 Annual Results. The Auditor also considers that there are material uncertainties on the impacts to the Company’s financial information before such allegations have been sufficiently investigated into. As such, the announcement on the 2025 Annual Results will not be published by 30 June 2025. The Company’s delay in announcing the 2025 Annual Results will constitute non-compliance with Rule 13.49(1) of the Listing Rules.

Accordingly, additional time is required for the Company to prepare the 2025 Annual Results. Discussions with the Auditor are ongoing. The Board, audit committee of the Company (the “**Audit Committee**”) and the management of the Company are doing their utmost to assist and cooperate with the Auditor to ensure that the 2025 Annual Results will be available as soon as practicable.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results in accordance with Rules 13.49(1) and (2) of the Listing Rules, it must announce its results based on the financial results which have yet to be agreed with the Auditor (so far as the information is available).

The Audit Committee requires more time to consider the unaudited management accounts of the Group for the year ended 31 March 2025, and therefore at this stage it would not be appropriate for the Company to publish such unaudited management accounts without allowing the Audit Committee sufficient time to consider the accounts.

## **POSSIBLE DELAY IN DESPATCH OF 2025 ANNUAL REPORT**

Pursuant to Rule 13.46(2) of the Listing Rules, the Company is required to despatch its annual report for the year ended 31 March 2025 (the “**2025 Annual Report**”) to the Shareholders no later than four months after the end of the financial year (i.e. on or before 31 July 2025).

Due to the delay in publishing the announcement on the 2025 Annual Results, there may be a possible delay in the despatch of the 2025 Annual Report. If the Company does not despatch the 2025 Annual Report by 31 July 2025, such failure will constitute non-compliance with Rule 13.46(2) of the Listing Rules.

## **BOARD MEETING**

Reference is made to the announcement of the Company dated 13 June 2025 in relation to a meeting of the Board to be held on 25 June 2025 for the purpose of, inter alia, approving the annual results of the Group for the year ended 31 March 2025, and considering the recommendation for payment of a final dividend.

The Board has held the meeting on 25 June 2025 as scheduled and the Board has resolved not to recommend the declaration of final dividend for the year ended 31 March 2025 (2024: nil).

## **GENERAL**

Save as disclosed above, there is no other inside information that has led to the delay in publishing the announcement on the 2025 Annual Results and the possible delay in the despatch of the 2025 Annual Report.

Further announcement(s) will be published in due course by the Company to inform the Shareholders and its potential investors of the expected dates of announcing the 2025 Annual Results and of the despatch of the 2025 Annual Report and/or any material development on the aforesaid matters.

The Board has assessed that the delay in announcing the 2025 Annual Results and in despatching the 2025 Annual Report would not have any material adverse effect to the Group's business and operation, which are continuing normally.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Shares has been suspended with effect from 9:00 a.m. on Tuesday, 15 April 2025 and will remain suspended until further notice.

The Company will make further announcements as and when appropriate in respect of the suspension.

**Shareholders, investors and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company**

By order of the Board  
**CLARITY MEDICAL GROUP  
HOLDING LIMITED**  
**WU Ting Yuk Anthony**  
*Non-Executive Director and Chairman*

Hong Kong, 25 June 2025

*As at the date of this announcement, the Board comprises Mr. JIANG Bo, Mr. HUI Yung Chris, Dr. TSE Wai Ip and Mr. LO Tsz Hong as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director and Ms. CHENG Jessica, Mr. WANG Can and Ms. CI Ying as independent non-executive Directors.*